Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGN ...

Cell replacement therapy offers new hope for millions of people affected by retinal degenerations (RDs)—a group of blinding ...

Eylea is prescribed to prevent vision loss from conditions like wet age-related macular degeneration and diabetic macular edema by targeting and blocking a protein called vascular endothelial ...

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which Apel ...